Skrzypiec-Spring Monika, Zubkiewicz-Kucharska Agnieszka, Pasińska Magdalena, Rabijewski Michał, Śmigiel Robert, Szeląg Adam
Department of Pharmacology, Wrocław Medical University, Wrocław, Poland.
Department of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wrocław Medical University, Wrocław, Poland.
Front Endocrinol (Lausanne). 2025 Aug 22;16:1648940. doi: 10.3389/fendo.2025.1648940. eCollection 2025.
Hypergonadotropic hypogonadism is usually caused by the impairment of the structure and function of the gonads, but there are cases caused by reduced stimulation by the follicle-stimulating hormone (FSH) as a result of abnormal variants of genes encoding the follicle-stimulating hormone or its receptor (FSHR). We present the case of an elite athlete with the c.2039A>G variant in one allele of the FSHR gene resulting in hypergonadotropic hypogonadism, low testicular volume, and reduced semen parameters, placing particular emphasis on the diagnostic process and the importance of correct diagnosis in the context of possible treatment with gonadotropins, which can significantly improve fertility, increase testosterone levels, and, in the case of athletes, obtain approval from the anti-doping organization for treatment that increases testosterone levels.
高促性腺激素性性腺功能减退通常由性腺的结构和功能受损引起,但也有因编码促卵泡激素(FSH)或其受体(FSHR)的基因异常变异导致FSH刺激减少而引起的病例。我们报告了一名精英运动员的病例,其FSHR基因的一个等位基因存在c.2039A>G变异,导致高促性腺激素性性腺功能减退、睾丸体积减小和精液参数降低,特别强调了诊断过程以及在可能使用促性腺激素治疗的情况下正确诊断的重要性,促性腺激素治疗可显著提高生育能力、提高睾酮水平,对于运动员而言,还可获得反兴奋剂组织对提高睾酮水平治疗的批准。